TargetBeta
SERPINA1
serpin family A member 1 · also AAT, A1A, PI1, alpha-1-antitrypsin · Serpin peptidase inhibitors
4 programs in company-led studies act on SERPINA1, from 4 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| ensitrelvirrule | Shionogi | phase 3 | 50 running | – | the studies' text |
| efdoralprin alfa | Sanofi | phase 2 | 21 running | – | the company's pipeline |
| CTX460rule | CRISPR Therapeutics | phase 2 | 11 running | – | the studies' text |
| Proteasome Inhibitor SHY-ONC6rule | SHY Therapeutics | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- alpha 1-Antitrypsin Deficiency, 2 programs
- COVID-19, 1 program
- Renal Insufficiency, 1 program
- Triple Negative Breast Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 15, 2027Proteasome Inhibitor SHY-ONC6 · SHY Therapeutics · phase 1 · NCT07705334
- Jun 30, 2028efdoralprin alfa · Sanofi · phase 2 · NCT05897424
- Jun 2030CTX460 · CRISPR Therapeutics · phase 2 · NCT07850076
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.